A study of the interaction of omeprazole and warfarin in anticoagulated patients.
作者信息
Unge P, Svedberg L E, Nordgren A, Blom H, Andersson T, Lagerström P O, Idström J P
机构信息
Department of Medicine, Sandviken Hospital, Sweden.
出版信息
Br J Clin Pharmacol. 1992 Dec;34(6):509-12. doi: 10.1111/j.1365-2125.1992.tb05656.x.
Abstract
- Thirty-five patients on continuous therapy with warfarin were given omeprazole 20 mg once daily and placebo each for 3 weeks according to a two-centre randomised double-blind cross-over design. 2. Blood samples were obtained once weekly during the run-in and follow-up periods as well as during the first 2 weeks of each treatment period, and twice during the last week of each treatment period. Plasma concentrations of R- and S-warfarin were measured by h.p.l.c. and the anticoagulant effect was assessed using the Trombotest. 3. Twenty-eight patients were evaluated. The mean plasma concentration of R-warfarin was increased by 9.5% during omeprazole treatment compared with placebo, while that of S-warfarin, the more active isomer, was unaffected. The coagulation time was not significantly changed (106 s during omeprazole and 98 s during placebo). Corresponding TT-values (Trombotest) were 8.8 and 9.9 (NS).
摘要
相似文献
1
A study of the interaction of omeprazole and warfarin in anticoagulated patients.
Br J Clin Pharmacol. 1992 Dec;34(6):509-12. doi: 10.1111/j.1365-2125.1992.tb05656.x.
2
Stereoselective interaction of omeprazole with warfarin in healthy men.
Ther Drug Monit. 1989;11(2):176-84. doi: 10.1097/00007691-198903000-00010.
3
A study of the interaction between omeprazole and cyclosporine in renal transplant patients.肾移植患者中奥美拉唑与环孢素相互作用的研究。
Br J Clin Pharmacol. 1993 Feb;35(2):156-60.
4
No effect of short-term omeprazole intake on acenocoumarol pharmacokinetics and pharmacodynamics.短期服用奥美拉唑对醋硝香豆素的药代动力学和药效学无影响。
Br J Clin Pharmacol. 1997 Oct;44(4):399-401. doi: 10.1046/j.1365-2125.1997.00600.x.
5
The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole.细胞色素P2C19在R-华法林药代动力学中的作用及其与奥美拉唑的相互作用。
Ther Drug Monit. 2008 Jun;30(3):276-81. doi: 10.1097/FTD.0b013e31816e2d8e.
6
Effect of omeprazole on the anticoagulant activity and the pharmacokinetics of warfarin enantiomers in rats.奥美拉唑对大鼠华法林对映体抗凝活性及药代动力学的影响。
Eur J Pharm Sci. 2003 Dec;20(4-5):439-49. doi: 10.1016/j.ejps.2003.09.007.
7
Propranolol steady-state pharmacokinetics are unaltered by omeprazole.奥美拉唑不改变普萘洛尔的稳态药代动力学。
Eur J Clin Pharmacol. 1987;33(4):369-73. doi: 10.1007/BF00637632.
8
The effect of oral omeprazole on the disposition of lignocaine.
Anaesthesia. 1994 Jun;49(6):497-500. doi: 10.1111/j.1365-2044.1994.tb03519.x.
9
Interaction between paracetamol and warfarin in patients: a double-blind, placebo-controlled, randomized study.对乙酰氨基酚与华法林在患者中的相互作用：一项双盲、安慰剂对照、随机研究。
Haematologica. 2006 Dec;91(12):1621-7.
10
Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.在一项三阶段、开放标签、多剂量、单周期研究中，研究了依沙佐匹坦醋酸酯对健康受试者华法林稳态药代动力学和药效学的影响。
Clin Ther. 2010 Jan;32(1):179-92. doi: 10.1016/j.clinthera.2010.01.014.
引用本文的文献
1
Comparative in vitro assessment of CYP2C19 inhibition by ilaprazole and conventional proton pump inhibitors using a high throughput fluorometric assay.使用高通量荧光测定法对伊拉普唑和传统质子泵抑制剂的CYP2C19抑制作用进行体外比较评估。
Sci Rep. 2025 May 25;15(1):18158. doi: 10.1038/s41598-025-02872-5.
2
Elevated INR in a COVID-19 patient after concomitant administration of azvudine and anticoagulants.新冠病毒感染患者同时服用阿兹夫定和抗凝剂后国际标准化比值升高。
Front Pharmacol. 2023 May 19;14:1191608. doi: 10.3389/fphar.2023.1191608. eCollection 2023.
3
Monitoring the distribution of warfarin in blood plasma.监测华法林在血浆中的分布情况。
ACS Med Chem Lett. 2012 Jun 20;3(8):650-2. doi: 10.1021/ml300112e. eCollection 2012 Aug 9.
4
Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update.质子泵抑制剂的药代动力学药物相互作用概况：最新进展。
Drug Saf. 2014 Apr;37(4):201-11. doi: 10.1007/s40264-014-0144-0.
5
Drug-drug interaction profiles of proton pump inhibitors.质子泵抑制剂的药物相互作用谱。
Clin Pharmacokinet. 2010 Aug;49(8):509-33. doi: 10.2165/11531320-000000000-00000.
6
Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.与右兰索拉唑缓释制剂（TAK-390MR）的药物相互作用研究，一种具有双重延迟释放制剂的质子泵抑制剂：四项随机、双盲、交叉、安慰剂对照、单中心研究的结果。
Clin Drug Investig. 2009;29(1):35-50. doi: 10.2165/0044011-200929010-00004.
7
Pharmacokinetic drug interaction profiles of proton pump inhibitors.质子泵抑制剂的药代动力学药物相互作用概况。
Drug Saf. 2006;29(9):769-84. doi: 10.2165/00002018-200629090-00002.
8
Safety of potent gastric acid inhibition.强效胃酸抑制的安全性。
Drugs. 2005;65 Suppl 1:97-104. doi: 10.2165/00003495-200565001-00013.
9
Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects.吉非贝齐对健康受试者中消旋华法林药代动力学和药效学的影响。
Br J Clin Pharmacol. 2005 Apr;59(4):433-9. doi: 10.1111/j.1365-2125.2004.02323.x.
10
Gastroesophageal reflux in children: pathogenesis, prevalence, diagnosis, and role of proton pump inhibitors in treatment.儿童胃食管反流：发病机制、患病率、诊断及质子泵抑制剂在治疗中的作用
Paediatr Drugs. 2002;4(10):673-85. doi: 10.2165/00128072-200204100-00004.
本文引用的文献
1
Purification and characterization of six cytochrome P-450 isozymes from human liver microsomes.从人肝微粒体中纯化和鉴定六种细胞色素P-450同工酶。
Biochemistry. 1983 Nov 8;22(23):5375-83. doi: 10.1021/bi00292a019.
2
Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+)ATPase.取代苯并咪唑通过阻断（H⁺+K⁺）ATP酶来抑制胃酸分泌。
Nature. 1981 Mar 12;290(5802):159-61. doi: 10.1038/290159a0.
3
Evidence for acid-induced transformation of omeprazole into an active inhibitor of (H+ + K+)-ATPase within the parietal cell.酸诱导奥美拉唑在壁细胞内转化为（H⁺+K⁺）-ATP酶活性抑制剂的证据。
Biochim Biophys Acta. 1984 Dec 19;778(3):549-58. doi: 10.1016/0005-2736(84)90406-1.
4
Stereoselective interaction of omeprazole with warfarin in healthy men.
Ther Drug Monit. 1989;11(2):176-84. doi: 10.1097/00007691-198903000-00010.
5
Warfarin as a probe of cytochromes P-450 function.
Drug Metab Rev. 1989;20(2-4):479-87. doi: 10.3109/03602538909103554.
6
Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype.遗传因素在地西泮代谢调节中的重要性：与S-美芬妥因而非异喹胍羟化表型的关系。
Clin Pharmacol Ther. 1989 Apr;45(4):348-55. doi: 10.1038/clpt.1989.40.
7
Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators.奥美拉唑代谢缓慢者也是美芬妥因S-羟化反应不良者。
Ther Drug Monit. 1990 Jul;12(4):415-6. doi: 10.1097/00007691-199007000-00020.
8
Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily.
J Pharmacol Exp Ther. 1990 Jan;252(1):442-7.
9
Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole.奥美拉唑治疗对奥美拉唑慢代谢者与正常快代谢者地西泮血浆水平的影响。
Clin Pharmacol Ther. 1990 Jan;47(1):79-85. doi: 10.1038/clpt.1990.12.
10
Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9.经cDNA表达的人肝细胞色素P4502C9对甲苯磺丁脲和苯妥英的羟化作用
Biochem Biophys Res Commun. 1991 Mar 29;175(3):1112-8. doi: 10.1016/0006-291x(91)91680-b.
Zotero 插件